Protective function of tocilizumab in human cardiac myocytes ischemia reperfusion injury
10.1016/S1995-7645(14)60186-3
- Author:
Hai-Feng CHENG
1
;
Da-Ming JIANG
1
;
Kai-Yu TAO
1
;
Min-Jian KONG
1
;
Yan FENG
2
Author Information
1. Department of Cardiovascular Surgery, The Second Affiliated Hospital of Medical College of Zhejiang University
2. Department of Interventional cardiovascular center, The Second Affiliated Hospital of Medical College of Zhejiang University
- Publication Type:Journal Article
- Keywords:
Human cardiac myocytes;
Ischemia-reperfusion injury;
Protection;
Tocilizumab
- From:
Asian Pacific Journal of Tropical Medicine
2015;8(1):48-52
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the protective function of tocilizumab in human cardiac myocytes ischemia-reperfusion injury. Methods: The human cardiac myocytes were treated by tocilizumab with different concentrations(1.0 mg/mL, 3.0 mg/mL, 5.0 mg/mL) for 24 h, then cells were cultured in ischemia environment for 24 h and reperfusion environment for 1 h. The MTT and flow cytometry were used to detect the proliferation and apoptosis of human cardiac myocytes, respectively. The mRNA and protein expressions of Bcl-2 and Bax were measured by qRT-PCR and western blot, respectively. Results: Compared to the negative group, pretreated by tocilizumab could significantly enhance the proliferation viability and suppress apoptosis of human cardiac myocytes after suffering ischemia reperfusion injury (. P<0.05). The expression of Bcl-2 in tocilizumab treated group were higher than NC group (. P<0.05), while the Bax expression were lower (. P<0.05). Conclusions: Tocilizumab could significantly inhibit apoptosis and keep the proliferation viability of human cardiac myocytes after suffering ischemia reperfusion injury. Tocilizumab may obtain a widely application in the protection of ischemia reperfusion injury.
